Fut, nem toborozFázis nélkül
Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage
A legfontosabb adatok
- Ki végzi
- DALIM TISSEN Co., Ltd.
- Hol
- Dél-Korea5 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 194 fő, tervezett
- Kezdés
- 2025. júl. 3.
- Várható befejezés
- 2027. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- CartiPRO
- Synovian®
- A regiszteradat frissítve
- 2026. október 5.
Ki vehet részt
- Életkor
- 19 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 43 feltétel megnézéseKevesebb
Ki vehet részt
- Age 19 years and older
- Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:; Age ≥50 years; Morning stiffness <30 minutes; Crepitus on active motion; Bony tenderness; Bony enlargement; No palpable warmth
- Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit
- Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening
- Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study
- Able to understand and complete efficacy assessment questionnaires
- Willing and able to provide written informed consent
Ki nem vehet részt
- History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
- Cancer diagnosis within 5 years prior to screening
- Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
- Intra-articular corticosteroid injection into target knee within 12 weeks
- Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
- Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
- Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
- Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
- Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
- Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
- Planned cell therapy or gene therapy to target joint
- Known hypersensitivity to investigational product or its components
- Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
- Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
- Inflammatory joint disease (e.g., septic arthritis)
- Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
- Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
- Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
- History of autoimmune disease
- Active infection requiring parenteral antibiotics
- History of psychiatric disorder or epilepsy
- History of cell therapy or gene therapy to target joint
- Dermatological disease at injection site or site deemed unsuitable for injection
- Cognitive impairment or dementia preventing informed consent
- Any other condition that makes the subject unsuitable for study participation per investigator judgment
- Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
- Abnormal laboratory values at screening:
- ALT, AST, BUN, or serum creatinine >2× upper limit of normal
- Body Mass Index (BMI) ≥32 kg/m²
- Radiographic evidence of definite loss of patellofemoral joint space
- Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
- Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
- Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
- Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
- Pregnant or breastfeeding women
- Participation in another clinical trial within 4 weeks
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.
A vizsgálat 2 csoportja
- Study GroupA vizsgált kezelés
Group applied with CartiPRO
Kezelés: CartiPRO
- Control groupMár használt kezelés, összehasonlításként
Group applied with Synovian®
Kezelés: Synovian®
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Long-term Efficacy and Safety of CartiPRO Injection to Alleviate Knee Pain in Patients With Osteoarthritis and/or Diverse Cartilage Defects: a Multicenter, Single-blind, Randomized, Non-inferiority, Sponsor Initiated Trial
- A regiszteradat frissítve
- 2026. október 5.